ArticleOncotarget2014
Minoxidil may suppress androgen receptor-related functions.
Article in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Comparative Effect of Conventional and Non-Conventional Over-the-Counter Treatments for Male Androgenetic Alopecia: A Systematic Review and Network Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Efficacy and safety of oral minoxidil in the treatment of alopecia: a single-arm rate meta-analysis and systematic review.Frontiers in pharmacology · 2025Pooled it
- Inhibitory Effects ofJournal of microbiology and biotechnology · 2026Article
- Minoxidil May be a Partial Agonist of Estrogen Receptor Alpha.microPublication biology · 2026Article
- Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.American journal of clinical dermatology · 2026Review
- Using the Mechanisms of Action Involved in the Pathogenesis of Androgenetic Alopecia to Treat Hair Loss.International journal of molecular sciences · 2025Review
- Phytochemicals for Hair Health Targeting Growth Signaling Molecules in Hair Follicular Stem Cells: A New Strategy for Hair Growth.Journal of microbiology and biotechnology · 2025Review
- Meloside A Protects Dermal Papilla Cells from DHT-Induced Damage via Androgen Receptor Modulation.Current issues in molecular biology · 2025Article
- Oral minoxidil for late alopecia in cancer survivors.Breast cancer research and treatment · 2024Article
- Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alopecia.Dermatology and therapy · 2023Article
- New Target for Minoxidil in the Treatment of Androgenetic Alopecia.Drug design, development and therapy · 2023Article
- Unrevealing the Potential ofMolecules (Basel, Switzerland) · 2022Article
- Article
- Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer.JAMA dermatology · 2020Article
- Amelioration of Androgenetic Alopecia by Algal Oligosaccharides Prepared by Deep-Sea Bacterium Biodegradation.Frontiers in microbiology · 2020Article
- Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.Breast cancer research and treatment · 2019Review
- Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer.JAMA dermatology · 2018Article
- Minoxidil Promotes Hair Growth through Stimulation of Growth Factor Release from Adipose-Derived Stem Cells.International journal of molecular sciences · 2018Article
- Article
- Minoxidil is a potential neuroprotective drug for paclitaxel-induced peripheral neuropathy.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although minoxidil has been used for more than two decades to treat androgenetic alopecia (AGA), an androgen-androgen receptor (AR) pathway-dominant disease, its precise mechanism of action remains elusive. We hypothesized that minoxidil may influence the AR or its downstream signaling. These tests revealed that minoxidil suppressed AR-related functions, decreasing AR transcriptional activity in reporter assays, reducing expression of AR targets at the protein level, and suppressing AR-positive LNCaP cell growth. Dissecting the underlying mechanisms, we found that minoxidil interfered with AR-peptide, AR-coregulator, and AR N/C-terminal interactions, as well as AR protein stability. Furthermore, a crystallographic analysis using the AR ligand-binding domain (LBD) revealed direct binding of minoxidil to the AR in a minoxidil-AR-LBD co-crystal model, and surface plasmon resonance assays demonstrated that minoxidil directly bound the AR with a K(d) value of 2.6 µM. Minoxidil also suppressed AR-responsive reporter activity and decreased AR protein stability in human hair dermal papilla cells. The current findings provide evidence that minoxidil could be used to treat both cancer and age-related disease, and open a new avenue for applications of minoxidil in treating androgen-AR pathway-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.